Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pharmacological intervention of the FGF-PTH axis as a potential therapeutic for craniofacial ciliopathies

CL. Bonatto Paese, CF. Chang, D. Kristeková, SA. Brugmann

. 2022 ; 15 (8) : . [pub] 20220816

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024997

Grantová podpora
R35 DE027557 NIDCR NIH HHS - United States

Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid2) for a human ciliopathy with both kidney and skeletal anomalies (orofaciodigital syndrome 14), we identified disruptions in the FGF23-PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. Although pharmacological intervention with the U.S. Food and Drug Administration (FDA)-approved pan-FGFR inhibitor AZD4547 alone rescued expression of the FGF target SPRY2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and teriparatide acetate, a PTH agonist and FDA-approved treatment for osteoporosis, resulted in molecular, cellular and phenotypic rescue of ciliopathic micrognathia in talpid2 mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024997
003      
CZ-PrNML
005      
20221031100211.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1242/dmm.049611 $2 doi
035    __
$a (PubMed)35818799
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bonatto Paese, Christian Louis $u Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA $u Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA $1 https://orcid.org/0000000159925209
245    10
$a Pharmacological intervention of the FGF-PTH axis as a potential therapeutic for craniofacial ciliopathies / $c CL. Bonatto Paese, CF. Chang, D. Kristeková, SA. Brugmann
520    9_
$a Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid2) for a human ciliopathy with both kidney and skeletal anomalies (orofaciodigital syndrome 14), we identified disruptions in the FGF23-PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. Although pharmacological intervention with the U.S. Food and Drug Administration (FDA)-approved pan-FGFR inhibitor AZD4547 alone rescued expression of the FGF target SPRY2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and teriparatide acetate, a PTH agonist and FDA-approved treatment for osteoporosis, resulted in molecular, cellular and phenotypic rescue of ciliopathic micrognathia in talpid2 mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.
650    _2
$a cilie $x metabolismus $7 D002923
650    12
$a ciliopatie $x farmakoterapie $x genetika $x metabolismus $7 D000072661
650    _2
$a lidé $7 D006801
650    _2
$a intracelulární signální peptidy a proteiny $x metabolismus $7 D047908
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    12
$a mikrognacie $x metabolismus $x patologie $7 D008844
650    _2
$a fenotyp $7 D010641
650    _2
$a proteiny $x metabolismus $7 D011506
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chang, Ching-Fang $u Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA $u Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA $1 https://orcid.org/0000000167542769
700    1_
$a Kristeková, Daniela $u Laboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, v.v.i., Czech Academy of Sciences, Brno 602 00, Czech Republic $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno 625 00, Czech Republic
700    1_
$a Brugmann, Samantha A $u Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA $u Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA $u Division of Plastic Surgery, Department of Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA $1 https://orcid.org/0000000268606450
773    0_
$w MED00173721 $t Disease models & mechanisms $x 1754-8411 $g Roč. 15, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35818799 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100209 $b ABA008
999    __
$a ok $b bmc $g 1854611 $s 1176287
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 15 $c 8 $e 20220816 $i 1754-8411 $m Disease models & mechanisms $n Dis Model Mech $x MED00173721
GRA    __
$a R35 DE027557 $p NIDCR NIH HHS $2 United States
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace